Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Eksterne analyser

Relesys: Cost levels to normalise after abnormal Q3 - ABG

Relesys

Dette er en ekstern analyse og afspejler ikke nødvendigvis vores perspektiv eller værdier.

Download analyse (PDF)
ARR in line (36% y-o-y growth); minor '23e-'25e top-line revisions
'23e EBITDA up 8% on abnormally low Q3 costs and slower hirings
Small '24e-'25e EBITDA revisions; positive long-term view reiterated


Minor '23e-'25e top-line revisions on reiterated guidance

We make minor changes to our '23e-'25e top-line estimates (<1%), meaning we remain a tad below the mid-points of the reiterated DKK 59m-64m FY'23 ARR guidance (ABGSCe DKK 60.8m) and the DKK 54m-60m revenue guidance (ABGSCe DKK 56.0m). Q3 ARR of DKK 54.8m was in line with ABGSCe (corresponding to strong 36% y-o-y growth), driven by low churn of ~3%, ~16% uplift, and new ARR of ~23%. Revenues of DKK 14.5m were 2% higher. On a further positive, the company's ongoing transition to a stronger focus on enterprise customers appears to be progressing according to plan. Relesys sees the potential for closing some enterprise customers before YE'23e, as well as a pipeline that remains strong.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.